Overview Financials News + Filings Key Docs Charts Ownership Insiders
|
|
Applied Therapeutics Inc. (APLT)
|
Add to portfolio |
|
|
|
| Price: |
$5.82
| | Metrics |
| OS: |
63.1
|
M
| |
|
|
| Market cap: |
$367
|
M
| |
|
|
|
Net cash:
|
$35.6
|
M
| |
$0.56
|
per share
|
|
EV:
|
$332
|
M
| | | |
| | | | | |
| TTM Valuation | | | |
|
EBITDA
|
($66.4)
|
M
| |
|
|
|
EBIT
|
($66.4)
|
M
| |
|
|
| EPS |
($1.33)
| |
|
|
|
|
| |
|
|
|
Recent News + Filings (All items)
|
Revenue Mix by Segment
|
Financial Summary (All financials)
| In millions, except per share items | Dec-31-22 | Dec-31-21 | Dec-31-20 | Dec-31-19 | Dec-31-18 | Dec-31-17 |
| Revenues | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 3.7 |
| Revenue growth | | | | | -100.0% | |
| Cost of goods sold | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 4.3 |
| Gross profit | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | -0.6 |
| Gross margin | | | | | | -15.7% |
| Research and development | 55.6 | 62.6 | 61.8 | 32.4 | 11.5 | |
| General and administrative | 27.3 | 43.0 | 32.7 | 13.2 | 2.0 | 0.6 |
| EBIT | -83.0 | -105.6 | -94.5 | -45.6 | -13.5 | -4.3 |
| EBIT margin | | | | | | -115.7% |
| Pre-tax income | -82.5 | -105.6 | -94.0 | -45.5 | -16.5 | -4.3 |
| Income taxes | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 |
| Tax rate | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% |
| Net income | -82.5 | -105.6 | -94.0 | -45.5 | -16.5 | -4.3 |
| Net margin | | | | | | -115.6% |
| |
| Diluted EPS | ($2.18) | ($4.12) | ($4.28) | ($3.55) | ($3.01) | ($0.79) |
| Shares outstanding (diluted) | 37.8 | 25.6 | 22.0 | 12.8 | 5.5 | 5.4 |
| |
| EBIT is a non-GAAP figure that excludes all non-recurring expenses: restructuring costs, asset impairments, IPR&D writeoffs, and other unusual charges. |
|
|